Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

PYXS has been the subject of a number of other research reports. Stephens boosted their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Royal Bank Of Canada lowered their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. HC Wainwright lifted their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Stock Up 1.5%

Shares of NASDAQ PYXS opened at $1.37 on Friday. The stock has a market cap of $85.30 million, a PE ratio of -0.86 and a beta of 1.45. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.55. The business has a 50-day moving average price of $1.49 and a 200 day moving average price of $2.50.

Hedge Funds Weigh In On Pyxis Oncology

Large investors have recently modified their holdings of the business. Maia Wealth LLC acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $25,000. Fox Run Management L.L.C. acquired a new position in Pyxis Oncology during the fourth quarter worth $26,000. Engineers Gate Manager LP acquired a new position in Pyxis Oncology during the fourth quarter worth $26,000. Catalyst Funds Management Pty Ltd purchased a new position in Pyxis Oncology in the second quarter worth $26,000. Finally, Avanza Fonder AB purchased a new position in Pyxis Oncology in the fourth quarter worth $31,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.